Treace Medical announces bunion treatment SpeedPlate gets 510k clearance

Treace Medical Concepts announced that its SpeedPlate Rapid Compression Implant System has received 510(k) clearance from the FDA to be used for fracture fixation, osteotomy fixation, and joint arthrodesis of the foot and ankle. The SpeedPlate System was designed for rapid delivery of titanium compression implants, serving as enabling fixation technology with Treace’s new Micro-Lapiplasty instrumentation which allows the patented Lapiplasty procedure to be performed through small, 2cm incisions. The SpeedPlate implant platform also serves as a versatile addition to the Company’s fixation portfolio, with broad compatibility with conventional Lapiplasty , Lapiplasty Mini-Incision and Adductoplasty procedures/systems. "We are pleased to announce 510(k) clearance of our SpeedPlate(TM) technology. SpeedPlate represents an exciting new fixation platform for Treace as we continue to invest in targeted R&D efforts aimed at making our Lapiplasty therapy less invasive, faster, and easier for surgeons to perform, reinforcing our mission to improve surgical outcomes for bunion patients and advance Lapiplasty as the standard of care," said John T. Treace, CEO, Founder, and Board Member. "As with any procedure involving smaller incisions and less tissue dissection, we believe our Micro-Lapiplasty SpeedPlate offering may translate to even faster patient recovery with less pain and swelling."